Embolism and thrombosis | Guidance and guideline topic

Everything NICE has produced on the topic of embolism and thrombosis. Includes related guidelines, NICE Pathways, quality standards and advice.

5 new

and

0 updated

products since January 2017.

Interventional procedures guidance

NICE Medtech innovation briefings

NICE Evidence summaries

Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73) May 2016

Medical technologies guidance

The geko device for reducing the risk of venous thromboembolism (MTG19) June 2014

NICE Guidelines

Quality standards

In development

Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913] (GID-TA10154) September 2018 Technology appraisal guidance
Venous thromboembolism - apixaban (acute medical illness) [ID310] (GID-TAG419) TBC Technology appraisal guidance
Venous thromboembolism - reducing the risk (full update) (GID-CGWAVE0795) March 2018 NICE guidelines
Venous thromboembolism (prevention) - rivaroxaban [ID463] (GID-TAG427) TBC Technology appraisal guidance
Venous thromboembolism (recurrent) - idraparinux sodium [ID395] (GID-TAG384) TBC Technology appraisal guidance

NICE Pathways - mapping our guidance

Venous thromboembolism

NICE Key therapeutic topics

Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) (KTT16) February 2016

Technology appraisal guidance

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275) February 2013

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245) January 2012

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341) June 2015

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249) March 2012

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157) September 2008

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327) December 2014

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355) September 2015

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354) August 2015

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256) May 2012

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170) April 2009

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261) July 2012

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) June 2013

Interventional procedures guidance

Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (IPG554) April 2016

Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers (IPG371) December 2010

Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (IPG349) June 2010

Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism (IPG400) June 2011

Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (IPG523) June 2015

Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524) June 2015

NICE Medtech innovation briefings

ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55) March 2016

The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25) March 2015

NICE Evidence summaries

Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73) May 2016

Medical technologies guidance

The geko device for reducing the risk of venous thromboembolism (MTG19) June 2014

NICE Guidelines

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (CG144) June 2012

Venous thromboembolism: reducing the risk for patients in hospital (CG92) January 2010

Quality standards

Venous thromboembolism in adults: diagnosis and management (QS29) March 2013

Venous thromboembolism in adults: reducing the risk in hospital (QS3) June 2010

In development

Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913] (GID-TA10154) September 2018 Technology appraisal guidance

Venous thromboembolism - apixaban (acute medical illness) [ID310] (GID-TAG419) TBC Technology appraisal guidance

Venous thromboembolism - reducing the risk (full update) (GID-CGWAVE0795) March 2018 NICE guidelines

Venous thromboembolism (prevention) - rivaroxaban [ID463] (GID-TAG427) TBC Technology appraisal guidance

Venous thromboembolism (recurrent) - idraparinux sodium [ID395] (GID-TAG384) TBC Technology appraisal guidance